2020.04.03
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe illness caused by the coronavirus disease 2019 (COVID-19).
2020.04.02
- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S. for advanced solid tumors and ...
2020.03.31
- Successfully completed initial public offering raising approximately $114.5 million in gross proceeds - Continued execution across broad pipeline portfolio; multiple clinical data readouts expected in 2020 - Company to host conference call and webcast, March 31 at 8:00 a.m. EDT
2020.03.30
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other territories - Partnership to include right of first negotiation on an additional I-Mab-discovered product candidate to be agr...
2020.03.27
Fernando J. Sallés, Ph.D., CLP®, Appointed to Lead I-Mab’s US and EU Business Development.
2020.03.23
I-Mab today announced the appointment of Gigi Feng as Vice President, Global Head of Corporate Communications, effective April 20th, 2020. Reporting to I-Mab’s Board of Directors, Feng will oversee all communications across I-Mab, partnering with the executive team to communicate the Company’s strat...
2020.03.13
-The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight "cytokine storm” during severe COVID-19 disease -The study to be conducted initially in the United States with planned expansion of study into other countries.
2020.01.17
SHANGHAI, China & ROCKVILLE, MD., January 16, 2020 – I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020.01.03
SHANGHAI, January 3, 2020 -- I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced the dosing of the first ...
2019.11.14
SHANGHAI, China – November 14, 2019 – I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that National ...